Literature DB >> 11902797

Poly(L-lysine) as a model drug macromolecule with which to investigate secondary structure and membrane transport, part I: Physicochemical and stability studies.

Montakarn Chittchang1, Hemant H Alur, Ashim K Mitra, Thomas P Johnston.   

Abstract

Low oral bioavailability of therapeutic peptides and proteins generally results from their poor permeability through biological membranes and enzymatic degradation in the gastrointestinal tract. Since different secondary structures exhibit different physicochemical properties such as hydrophobicity, size and shape, changing the secondary structure of a therapeutic polypeptide may be another approach to increasing its membrane permeation. Poly(L-lysine) was used as a model polypeptide. The objectives of this study were to induce secondary structural changes in poly(L-lysine) and to determine the time course over which a given conformer was retained. In addition, the hydrophobicity of each secondary structure of poly(L-lysine) was assessed. The circular dichroism (CD) studies demonstrated that the conditions employed could successfully induce the desired secondary structural changes in poly(L-lysine). The alpha-helix conformer appeared to be more stable at 25 degrees C whereas the beta-sheet conformer could be preserved at 37 degrees C. On the other hand, the random coil conformer was retained at both temperatures. Significant losses of the alpha-helix and the beta-sheet conformers were observed when the pH was reduced. The change in ionic strength did not affect any of the conformers. The octanol/buffer partitioning studies indicated that the alpha-helix and the beta-sheet conformers exhibited significantly different (P < 0.05) hydrophobicities. In conclusion, variation of pH and temperature conditions can be used to induce secondary structural changes in poly(L-lysine). These changes are reversible when the stimuli are removed. The alpha-helix and the beta-sheet conformers of poly(L-lysine) are more lipophilic than the native random coil conformer. Thus, poly(L-lysine) may represent an ideal model polypeptide with which to further investigate the effects of secondary structure on membrane diffusion or permeation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11902797     DOI: 10.1211/0022357021778556

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Interplay of secondary structure and charge on the diffusion of a polypeptide through negatively charged aqueous pores.

Authors:  Montakarn Chittchang; Ashim K Mitra; Thomas P Johnston
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

2.  An Environmentally Sensitive Fluorescent Dye as a Multidimensional Probe of Amyloid Formation.

Authors:  Emma V Yates; Georg Meisl; Tuomas P J Knowles; Christopher M Dobson
Journal:  J Phys Chem B       Date:  2016-02-29       Impact factor: 2.991

3.  Variants of Escherichia coli Subtilase Cytotoxin Subunits Show Differences in Complex Formation In Vitro.

Authors:  Maike Krause; Katharina Sessler; Anna Kaziales; Richard Grahl; Sabrina Noettger; Holger Barth; Herbert Schmidt
Journal:  Toxins (Basel)       Date:  2019-12-03       Impact factor: 4.546

4.  Secondary structure of end group functionalized oligomeric-l-lysines: investigations of solvent and structure dependent helicity.

Authors:  Merve Basak Canalp; Annette Meister; Wolfgang H Binder
Journal:  RSC Adv       Date:  2019-07-12       Impact factor: 4.036

5.  The effect of a peptide-containing synthetic lung surfactant on gas exchange and lung mechanics in a rabbit model of surfactant depletion.

Authors:  Johann M van Zyl; Johan Smith; Arthur Hawtrey
Journal:  Drug Des Devel Ther       Date:  2013-03-11       Impact factor: 4.162

6.  Influence of temperature and salt on coacervation in an aqueous mixture of poly-L-lysine (PLL) and poly-(sodium styrene sulfonate) (PSSNa).

Authors:  Imen Naassaoui; Adel Aschi
Journal:  Eur Biophys J       Date:  2021-05-28       Impact factor: 1.733

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.